Johnson & Johnson told to throw out 60M COVID-19 shots made at troubled Emergent site: report ‘Place them in the trash’: FDA warns against using Innova’s rapid COVID-19 antigen tests GSK reveals 26 million Americans skipped routine vaccinations last year, quantifying widely held suspicions HHS gives providers flexibility on spending COVID-19 relief funds, updates reporting requirements COVID-19 tracker: EU doesn't expect J&J to reach June vaccine delivery goal as U.S. scraps millions of doses HHS to give $424M to rural health clinics for COVID-19 tests, mitigation strategies Oxford spinout spies the hidden mechanics of DNA and disease with single-pair resolution method Lilly's internal probe into Branchburg, New Jersey, plant found company didn't mislead FDA, but DOJ investigation remains: report Featured Story | By Noah Higgins-Dunn The FDA has instructed Johnson & Johnson to toss about 60 million COVID-19 vaccines made at Emergent BioSolutions' troubled factory in Baltimore, Maryland, the New York Times reports. read more |
| |
|---|
|
| | Benefits of Decentralized Clinical Trials To execute decentralized research strategies, sponsors are turning to an integrated supply chain solution known as Direct-to-Patient Services. This service allows patients to participate in clinical trials from their homes by providing them with study drugs and care where they live. Learn more. |
Top Stories By Conor Hale The FDA issued a stark warning to the public urging them to stop using rapid COVID-19 antigen tests developed by Innova Medical Group, the company previously tapped by the U.K. for hundreds of millions of kits. read more By Beth Snyder Bulik More than 26 million Americans skipped doses of standard recommended vaccines in 2020, according to GlaxoSmithKline. That's 8.8 million adolescents and 17.2 million adults who missed vaccines between January and November, discovered through claims analysis by Avalere Health commissioned by GSK. read more By Robert King HHS gave providers flexibility on a key June 30 deadline to spend all their COVID-19 relief funds, giving recipients more time to use the funds if they were received after June 30, 2020. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner The European Union no longer expects Johnson & Johnson to reach its goal of delivering 55 million vaccines to the bloc by the end of June. Meanwhile, U.S. regulators told the company to scrap about 60 million doses after the production mishap at the troubled Emergent plant. And more headlines. read more By Robert King HHS is giving rural health clinics $424.7 million to increase their supplies of COVID-19 tests and to boost strategies to mitigate the virus. read more By Conor Hale Nucleome Therapeutics has found a new way to depict and analyze DNA with super-fine resolution, allowing them to peer into “the dark matter of the human genome” and the molecular basis of many diseases. What they hope to find are answers about COVID-19 severity—and new drug targets for multiple sclerosis and rheumatoid arthritis. read more By Noah Higgins-Dunn When Eli Lilly last month revealed that the U.S. Justice Department issued a subpoena into its manufacturing facility in Branchburg, New Jersey, the drugmaker's own independent investigation had already wrapped up and concluded the company didn't make false statements to the FDA, Reuters reports. read more | | Webinar: Accelerating NASH Clinical Trials Tuesday, June 15 | 10am ET / 7am PT Join industry leaders for a webinar dedicated to overcoming key challenges presented in NASH drug development. We’ll explore key considerations for liver biopsy collection and interpretation, emerging non-invasive biomarkers, and the connection between clinical practice and drug development. Register now. |
|
